Dec. 6, 2018 Price forecast | 2 weeks: 3.98% | 1 month: 4.47% | 3 months: 4.78%


AQST stock forecast

Our latest prediction for Aquestive Therapeutics, Inc.'s stock price was made on the Dec. 6, 2018 when the stock price was at 8.75$.

In the short term (2weeks), AQST's stock price should outperform the market by 3.98%. During that period the price should oscillate between -8.46% and +14.91%.

In the medium term (3months), AQST's stock price should outperform the market by 4.78%. During that period the price should oscillate between -17.22% and +33.80%.


About Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.

At the moment the company generates 54M USD in revenues.

On its last earning announcement, the company reported a loss of -2.56$ per share.

The book value per share is 0.94$

Aquestive Therapeutics, Inc. website


Three months stock forecastDec. 6, 2018


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
54M 64.20% -53M -99.00% -64M -2.56 - - 25M 0.94 -49M -1M -51M